Big Questions: Cannabis & Psychedelics

​Explore the intersection of 'Cannabis and psychedelics' at unDavos. This combined panel delves into the latest trends, medical advancements, and regulatory challenges in both sectors. Ideal for those interested in the evolving landscapes of these transformative industries.

​-

​11:00 am - 12:00 pm | Cannabis in US ,CH and the EU

​Where do we stand, and what lies ahead? Join us to explore the industry's current state, challenges, and future potential, including insights from leaders in their fields. A vital discussion on shaping policy and market trends, applicable beyond cannabis.

• ​Maximilian Plank, Trustsquare (moderator)

• ​Luc Richner, Cannavigia, Software Supply Chain

• ​Dr. Gavin George, Puregene AG, Research & Producer

• ​Raffael Kuehne, Alpina Pharma AG, Pharmaceutical Producer

• ​Niclas Butz, CEO, Feroplant SA. Producer, IOT Blockchain Certificate Solution

• ​Michela Mastropietro; Swiss Queen & KannaSwiss, Managing Partner; Product development and Brands

• ​Bill Marcus, Institutional Investor US

​-

​12:00 pm - 1:00 pm | Altered States of Mental Health: the State of Psychedelic-Assisted Therapy Today & Future Outlook

​After nearly 40 years of advocacy and research, MAPS recently submitted the first ever NDA to the FDA for MDMA-assisted therapy for PTSD. Where does psychedelic-assisted therapy stand today and what is the trajectory for the next year, 5 year, and 10 years.

• ​Anne Philippi, Founder/Creator, The New Health Club

• ​RickDoblin, Founder/President, Multidisciplinary Association for Psychedelic Studies (MAPS)

• ​Davor Kosanic (PhD), CEO/Co-founder, Reconnect Labs

• ​Maria Velkova, Managing Partner, Tabula Rasa Ventures

• ​Florencia Bollini, CEO/Founder, NANA Health

• ​Greg Carette, CEO/Founder, True Nature Retreat Center